Bakhu Holdings, Corp. Announces Major Licensing Agreement for Cell Extraction of Phytocannabinoids
December 28, 2018 at 12:26 pm
Share
Bakhu Holdings, Corp. announced the signing of an agreement for the exclusive license of certain patents and intellectual property associated with technical information to produce phytocannabinoids for use in medical and wellness treatments. The license is with Cell Science Ltd., Republic of Cyprus, for the United States, Canada, Mexico, all countries in the Caribbean Sea and all other countries north of the Panama/Columbia border (including the entire nation of Panama) in exchange for 210,000,000 restricted shares of Common Stock of the Company. This is the initial step in management’s business plan to investigate the strategic acquisition of cell extraction related licenses developed by others than can be converted into processes to be licensed to large companies for sale to the public.
Bakhu Holdings, Corp. is a development-stage company. The Company hold a license from Cell Science to plant cell-extraction and replication technology and related equipment, processes, and formulations (the Licensed Science), to produce, manufacture, and sell cannabis-related byproducts - sometimes referred to as cannabinoids in North America, Central America, and the Caribbean for medical, food additive, and recreational uses. The Company is focused on testing and commercializing cannabis plant cell-extraction and replication technologies under a technology license granted by Cell Science. It also intends to sublicense the Licensed Science to third party sub-licensees. The Company has not generated any revenue.
BAKHU HOLDINGS, CORP. 
